Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit

Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit

Appointment supports AstraZeneca's $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030

AstraZeneca has named Rick R. Suarez Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit.

Suarez will lead the execution of the Company's previously announced $50 billion US research, development and manufacturing investment, including construction of a $4.5 billion manufacturing facility in Virginia, AstraZeneca's largest single manufacturing investment globally.

The investment underpins AstraZeneca's goal of generating $80 billion in Total Revenue by 2030, with half expected to come from the US, the Company's largest market.

Suarez said: "We are operating at a moment of unprecedented scientific opportunity. Our responsibility is to translate that science into results for patients and for the US healthcare system. By strengthening our US manufacturing and R&D footprint, we will expand access to innovative medicines, create highly skilled jobs, and deliver long-term value."

Suarez will have full responsibility for AstraZeneca's US BioPharmaceuticals organization, with accountability for performance, growth and execution across the portfolio.

Suarez brings more than 20 years of experience in the US healthcare sector, with leadership roles spanning commercial, medical and market access functions at AstraZeneca. He returns to the US after serving as Country President for Spain since 2020, where he led one of AstraZeneca's strongest performing European markets. He expanded Spain's role in global clinical development and positioned Barcelona as a strategic hub for innovation.

During his tenure in Spain, Suarez established a new global hub in Barcelona and launched the AstraZeneca Healthcare Innovation Hub, committing more than €10 million to digital health and data-driven initiatives focused on translational innovation.

Suarez will be based at AstraZeneca's US headquarters in Wilmington, Delaware. His appointment is effective immediately.

Biographical information

Rick Suarez was born in the United States and grew up in New Haven, Connecticut. He joined AstraZeneca in 1999 as a pharmaceutical sales specialist and has worked across many functions of the business including marketing, medical affairs and market access.

Notes

AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca-us.com and follow the Company on social media @AstraZeneca .

Media Inquiries
Fiona Cookson +1 212 814 3923

US Media Mailbox: usmediateam@astrazeneca.com

News Provided by Business Wire via QuoteMedia

AZN
The Conversation (0)
AstraZeneca

AstraZeneca

AstraZeneca is a global science-led biopharmaceutical company that focuses on the discovery development and commercialisation of prescription medicines.

AstraZeneca is a global science-led biopharmaceutical company that focuses on the discovery development and commercialisation of prescription medicines. Keep Reading...

Last Mile Holdings Ltd. Changes Name to AZN Capital Corp.

AZN Capital Corp. (the "Company" or "AZN") (TSXV: AZN.V) (OTC: AZNVF) announces that it has changed its name from "Last Mile Holdings Ltd." to "AZN Capital Corp." In connection with the name change, the Company's trading symbol on the TSX Venture Exchange will be changed to "AZN.V" upon the... Keep Reading...

Myriad Gets FDA Approval for Metastatic Pancreatic Cancer Drug

Myriad Genetics (NASDAQ:MYGN) confirmed that the US Food and Drug Administration (FDA) has approved its diagnostic test, BRACAnalysis CDx, for use to identify patients with metastatic pancreatic cancer who have a germline BRCA mutation and are candidates for treatment with Lynparza (olaparib).... Keep Reading...

Interactive Chart

Latest Press Releases

Related News